Introduction {#s1}
============

Biologic agents, introduced in the late 1990s, have improved the treatment outcomes of autoimmune disease, inflammatory disease, and tumour therapy ([@B5]; [@B46]; [@B7]). Additionally, the application of biological processes involving recombinant DNA technology, which allowed the production of proteins like cytokines and humanized antibodies, must be credited ([@B37]).

These drugs include tumour necrosis factor (TNF) inhibitors (e.g. adalimumab, certolizumab, etanercept, golimumab and infliximab), anti-CD28 agent (abatacept), anti-cytokine agents (anakinra and tocilizumab), anti-B-cell agent (rituximab), T-cell modulating agent (alefacept), and inhibitors of interleukin (IL)-12 and IL-23 (ustekinumab) ([@B52]). Indications for use vary between the countries in which they have been approved for marketing.

The wide use of biological agents in modern medicine is a challenge for physicians and requires constant learning, with distinct knowledge and familiarity of the disease to be treated. Additionally, these biological agents are expensive and compel the physicians to consider the economic burden on patients. Biologic agents have been associated with high rates of total adverse events and withdrawals due to adverse events ([@B61]).

Tumor Necrosis Factor-alpha (TNFα) is essential for increasing phagocytic activity of macrophages and other killer cells; therefore, anti-TNFα medication can lead to common and opportunistic infections ([@B10]). These include tuberculosis, atypical mycobacteriosis, listeriosis, histoplasmosis, aspergillosis, pneumocystis, and legionellosis ([@B43]).

There is increasing evidence of the paradoxical induction of autoimmune processes associated with biological agents ([@B34]; [@B29]; [@B28]). Autoimmune diseases secondary to biological therapies comprise a variety of both, systemic illnesses including lupus, vasculitis, sarcoidosis, and antiphospholipid syndrome ([@B48]). Biological agents have also been associated with organ-specific autoimmune processes including interstitial lung disease, uveitis, optic neuritis, peripheral neuropathies, multiple sclerosis, and autoimmune hepatitis ([@B24]).

The majority of adverse effects manifest between one month to one year after initiating the therapy with a biological agent; however, they may also manifest years after treatment suspension ([@B37]). Biological agents may also manifest adverse effects that are yet unknown, suggesting that monitoring of ongoing patients is essential ([@B46]; [@B59]; [@B21]; [@B13]).

Patient reports are an important source of information on patient safety ([@B17]; [@B33]) and are useful in evaluating the adverse events ([@B26]; [@B72]). In Brazil, patients reported one or more adverse reactions associated with biological agents in 67% of the cases. These patients had no close clinical monitoring ([@B35]; [@B4]).

To further elucidate the adverse effects and predisposing factors associated with the use of biologics in clinical practice, we performed an observational study in patients with psoriatic arthritis (PsA) and/or rheumatoid arthritis (RA) who had been using the same biological agent for at least six months. The main objective was to evaluated the medium- and long-term safety of biologics in patients from a middle-income country.

Methods {#s2}
=======

Design and Setting {#s2_1}
------------------

We utilized a retrospective longitudinal design to investigate the adverse drug reactions (ADRs) ([@B21]) occurring in patients using long-term biologics (abatacept, adalimumab, efalizumab, etanercept, infliximab, rituximab, and tocilizumab) for treatment of PsA and RA in Brazil. The protocol was authorized by the Health State Department and approved by the Ethics Committee for Clinical Research of University of Sorocaba (August 17, 2009; protocol number 011/2009). Each patient provided an informed consent.

Definitions {#s2_2}
-----------

We defined ADR as "a response to a medicine or medicinal product that is noxious and unintended, and which occurs in doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease or for the modification of physiological function" ([@B65]). Therefore, we excluded events that resulted from drug errors, therapeutic failures, intentional or accidental poisoning, and drug abuse.

A serious adverse event (SAEs) was defined under the same code as 'any untoward medical occurrence that at any dose results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; creates persistent or significant disability/incapacity, or a congenital anomaly/birth defect' ([@B27]).

Eligibility Criteria {#s2_3}
--------------------

Eligible patients were those who underwent treatment with biologics for PsA/RA for at least 6 months, during 2003--2011.

Identification of Patients and Collection of Patient Data {#s2_4}
---------------------------------------------------------

To identify eligible patients, two researchers abstracted data from all the dispensing orders from the database of the government (CODES-SP). The patients with PsA were identified by ICD code M07, and those with RA were identified by ICD code M05. Patient details such as name, address, telephone number, gender, age, healthcare provider, type of biologic dispensed, and duration of treatment and diagnoses were collected.

We contacted these patients by telephone, and if they proved eligible and agreed to participate in the study, we conducted interviews by telephone using a questionnaire. The questionnaire included the following: name of the drug that patient was using for the treatment of PsA and RA; time of diagnosis of the disease; comorbidities; adverse drug reaction and whether it led to discontinuing medications; and whether patients was informed about the risk of taking such drugs.

Interviews were conducted by telephone using computer-assisted telephonic interview technology with a microcomputer handset with headphones. This system allows recording and monitoring of the conversation. Research staff working in pairs independently recorded data from the interviews, with discrepancies (if any) resolved by the principal investigator (LCL). This interview approach was developed by local dermatologists and rheumatologists in accordance with the recommendations of Brazilian and others important guidelines. Each interviewer (pharmacists) received training on use of language, related to each question in the interview schedule.

In order to dispense the biologics drugs in the pharmacy of the government, all pharmacists monitoring the patients with a formal structured checklist for ADR validated by rheumatologist and dermatologists.

We crosschecked patients' reports with data obtained from pharmacy records and from the database of the government. If discrepancies were found between sources of information, we considered the information from the pharmacy records as definitive. Definitive information about the name of the biologic and the duration of its use was obtained from the pharmacy, and definitive information regarding the time of diagnosis, use of previous medicines, and laboratory results were obtained from the patient.

This study is a part of a protocol published elsewhere ([@B4]; [@B59]).

ADR Reporting {#s2_5}
-------------

We collected information regarding the reported ADRs to understand their onset, nature of the reaction (system or organ affected), causality ([@B44]), and severity ([@B27]). The Naranjo algorithm ([@B44]) provided guidance for establishing causality and ADRs were ranked in three categories (definite, probable, and possible). The ADRs ranked as "definite" and "probable" were classified as likely caused by the biological agent. Pairs of reviewers (SBF, BCAB, FSDF, MCC) independently classified potential ADRs as "present" or "absent," and if present, classified them according to the causality classification. In case of disagreement a third reviewer (LL) provided adjudication.

Predisposing Factors {#s2_6}
--------------------

We considered the following variables as possible predisposing factors for ADRs. For each factor, we priori postulated the direction of the possible effects: i) **age** (older \[≥60 years\] versus younger \[19--59 years\], with a higher risk in older) ([@B20]), ii) **presence of comorbidities** (none versus one or more, with a higher risk in one or more illnesses) ([@B37]), iii) **diagnosis of more than one immunosuppressive disease** (only one versus more than one, with a higher risk for diagnostic with one or more) ([@B7]), iv) **concomitant use of other medications** (none versus one versus two or more, with a higher risk with more than one medication) ([@B20]), v) **concomitant use of disease modifying anti rheumatic drugs---DMARD** (none versus one or more, with a higher risk with more than one DMARD) ([@B37]), vi) **physician provided warnings regarding risk of medication** (higher risk when warnings were provided) ([@B20]), vii) **health insurance** (private versus public health insurance, with a higher risk for private insurance) ([@B36]), viii) **biological agent**, iv) **duration of use of biologics** (6 to 12 months versus 13 months or more).

Follow-Up and Clinical Monitoring {#s2_7}
---------------------------------

Clinical monitoring was done only in patients who were taking biologics during the interviews. We referred the guidelines of a few countries, such as Brazil ([@B2]; [@B1]), England ([@B60]), Canada ([@B3]), Germany ([@B67]), European League against Rheumatism -- EULAR ([@B22]), Group for Research and Assessment of Psoriasis and Psoriatic Arthritis -- GRAPPA ([@B8]) and took into account the common recommendations such as medical consults, laboratory blood examination, and radiograph.

As there is lack of consensus regarding the best interval for patient monitoring, we adopted the recommendations present in the Brazilian clinical protocols of the time, which considers as follows: **i) number of consults** (at least two annual medical consults); **ii) laboratory blood examination** (complete Blood Count, liver function tests and C-Reactive Protein test performed once a year) and **iii) radiography** (at least once a year). The IGRA sign test (interferon gamma release assay) was only introduced in public health service in 2014.

Owing to their high cost, biologics are only provided by government pharmacies, and therefore the follow-up was in accordance with the Brazilian official protocol. At the time of the study, annual radiography was considered as a test for monitoring tuberculosis progression, a condition common in Brazil, given the high number of patients acquired immunodeficiency syndrome (AIDS) in the general population.

Statistical Analysis {#s2_8}
--------------------

Initially, we obtained the descriptive statistics of the variables studied through frequencies. Later, the variables were stratified by patients, with and without ADRs and SAEs. We calculated the prevalence ratio (PR) to detect factors associated with the risk of ADRs using a Poisson regression.

We used with bivariate analysis (unadjusted) as a first step, and then, the analysis was adjusted for age, presence of comorbidities and use of other concomitant drugs. A significance level of *p* \< 0.05 and a confidence interval of 95% were adopted. All analyses were performed using STATA software.

Results {#s3}
=======

Of the 305 patients identified for using biologics for PsA or RA, 10 patients refused to participate, 13 were deceased and 14 used biological agent for less than 6 months. The resulting group of interviewees included, 268 plaintiffs of whom 158 (58.9%) were still using a biological agent at the time of the interview ([**Figure 1**](#f1){ref-type="fig"}).

![Flow diagram of the steps of the sample composition.](fphar-10-00965-g001){#f1}

[**Table 1**](#T1){ref-type="table"} presents characteristics of the patients with PsA and RA. Most of the patients were female (73.1%), less than 60 years old (mean age 55.8 ± 13), with rheumatoid arthritis only (73.1%), with one or more comorbidity (51.5%), using the biologic for 13 to 36 months (mean duration 35.7 ± 20).

###### 

Characteristics of the patients with psoriatic arthritis and rheumatoid arthritis.

  ---------------------------------------------------------------
  Patients                                           n (%)\
                                                     268 (100%)
  -------------------------------------------------- ------------
  **Sex**                                            

   Female                                            196 (73.1)

   Male                                              72 (26.9)

  **Age**                                            

   19--59                                            156 (58.2)

   60 or more                                        112 (41.8)

   mean ± sd                                         55.8 ± 13

  **Diagnostic**                                     

   Psoriatic arthritis only                          63 (23.6)

   Rheumatoid arthritis only                         196 (73.1)

   RA+PsA                                            9 (3.3)

  **Comorbidity\***                                  

   None                                              130 (48.5)

   1 or more                                         138 (51.5)

   Psoriasis                                         52 (37.7)

   Cardiovascular                                    61(44.2)

   Metabolic                                         34 (24.6)

   Skeletal muscle                                   35 (25.4)

   Others                                            28 (20.3)

  **Duration use of biologic agents (months)**       

   6 -- 12                                           40 (14.9)

   13 -- 36                                          133 (49.6)

   37 or more                                        95 (35.4)

   mean ± sd                                         35.7 ± 20

  **Health care**                                    

   Private                                           56 (20.9)

   Public                                            212 (79.1)

  **Concomitant use of drugs with biologic agent**   

   None                                              81 (30.2)

   1                                                 73 (27.2)

   2 or more                                         114 (42.6)

  **DMARD used with biologic agent**                 

   metrotexate                                       57 (21.3)

   corticosteroids                                   24 (8.9)

   Others                                            64 (23.9)

  **Time since diagnostic of disease RA/PSAR**       

   \<1 years                                         5 (1.9)

   1--3 years                                        9 (3.3)

   3--5 years                                        31 (11.6)

   \>6 years                                         223 (83.2)
  ---------------------------------------------------------------

\*Patients may have more than one comorbidity.

PsA, Psoriatic arthritis; RA, rheumatoid arthritis.

Patients with RA showed different comorbidities as compared to those with PsA. Approximately, 102 (52%) patients with RA showed comorbidities and 46 (45.1%) had cardiovascular diseases. Twenty-two (21.5%) patients had metabolic diseases (mainly diabetes and obesity), while 17 (16.6%) had muscle pain that rendered work disabilities. On the other hand, 16 (25%) patients with PsA showed comorbidities and 8 (50%) had cardiovascular disease, 6 (37.5%) had dermatological problems, 4 (25%) had inflammatory bowel disease, 3 (18.8%) had metabolic disease, 3 (18.8%) had musculoskeletal problems including osteoporosis and ophthalmic disorders was observed in 2 patients (12.5%).

[**Table 2**](#T2){ref-type="table"} depicts the characteristics of the adverse events in patients taking biological agents. Of the 268 patients, 116 (43.3%) experienced one or more adverse events related to the use of biological agents, at the rate of 1.6 events per patient. The most frequently \[n = 73 (27.2%)\] reported ADRs were administration site reactions (hypersensitivity reactions and cytokine-release syndrome), followed by incidences of respiratory and other types of infections \[n = 30 (11.2%)\] (opportunistic infections, urinary tract infections, skin infections, other systemic fungal infections and meninges infection)and effects on nervous system \[n = 22 (8.2%)\] (headaches and neuropathies). Of 116 patients with at least one ADR, 29 (25%) experienced SAE. The main causes for SAE included serious infections, malignancies and major cardiovascular events. There was no case of tuberculosis. We could not access the medical records to gain further details about these events. Eight patients required hospitalization, 6 had prolongation in existing hospitalization and 8 experienced life-threatening events.

###### 

Characteristics of adverse events in patients taking biological agents to treat psoriatic arthritis and rheumatoid arthritis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                      abatacept\   adalimumab\   efalizumab\   etanercept\   infliximab\   rituximab\   tocilizumab\   TOTAL\                                               
                                                                 (n = 10)     (n = 127)     (n = 9)       (n = 52)      (n = 42)      (n = 25)     (n = 3)        (n = 268)                                            
  -------------------------------------------------------------- ------------ ------------- ------------- ------------- ------------- ------------ -------------- ----------- ---- ---- ---- ---- --- --- ------------ -----
  **Adverse events\* n (%)**                                     6            9             91            188           5             9            37             73          24   55   16   27   2   6   181 (67.5)   367

  **Adverse event related with biologic agent\*\***              3            3             65            115           2             3            23             27          15   37   7    9    1   2   116 (43.3)   186

   *Administration site reactions¨*                              1            1             46            49            1             1            18             20          5    12   2    3    0   0   73 (27.2)    76

   *Respiratory infections and other types of infection* *^+^*   1            1             22            30            1             1            1              1           5    5    0    0    0   0   30 (11.2)    38

   *Nervous System* *^&^*                                        0            0             9             9             0             0            1              1           8    8    3    3    1   1   22(8.2)      22

   *Cardiovascular*                                              0            0             3             11            0             0            2              4           1    5    1    1    1   1   8 (3.0)      22

   *Metabolic*                                                   0            0             3             5             0             0            1              1           1    1    0    0    0   0   5 (1.9)      7

   *Gastrointestinal tract*                                      0            0             5             6             1             1            0              0           1    3    1    1    0   0   8 (3.0)      11

   *Immune*                                                      1            1             5             5             0             0            0              0           3    3    1    1    0   0   10 (3.7)     10

  **SAE (n = 29)**                                                                                                                                                                                                     

   *Inpatient*\                                                  0                          10                          1                          3                          1         0         0       15 (5.6)     
   *Hospitalization*                                                                                                                                                                                                   

   *Prolongation of existing hospitalization*                    0                          5                           0                          1                          0         0         0       6 (2.2)      

   *Life-threatening* *^&&^*                                     0                          5                           0                          1                          1         1         0       8 (3.0)      

  **Withdraw due ADRs**                                          0                          7                           0                          1                          7         0         0       15 (5.6)     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*A patient could have more than one event for system.*

ADR, adverse drug reactions; SAE, serious adverse event.

^\*^Adverse events ranked as possible, probable and definite.

^\*\*^Adverse event ranked as only definite or probable.

¨Hypersensitivity reactions and cytokine-release syndrome.

^+^Opportunistic infections, infections of the urinary tract, infections of the skin, other systemic fungal infections and infection of the meninges.

^&^Headache and neuropathies.

^&&^Life-threatening: requires inpatient hospitalization or prolongation of existing hospitalization; creates persistent or significant disability/incapacity, or a congenital anomaly/birth defect' ([@B27]).

[**Table 3**](#T3){ref-type="table"} shows the characteristics of population of the study with respect to predisposing factors of ADR and the association with ADRs. Overall, rituximab showed less risk to ADR \[PR 0.42, 95% CI (0.18--0.96); *p* = 0.04\] than other agents. The factors such as age, private healthcare assistance, provision of information about risk of ADRs, showed no association with ADRs.

###### 

Association between predisposing factors and ADRs.

  -----------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                         N-ADR   ADR\*   PR 95% IC\          P value   PR 95% IC\          P value
                                                                          Unadjusted                    Adjusted            
  ------------------------------------------------------- ------- ------- ------------------- --------- ------------------- ---------
  **Patients n (%)**                                      153     115                                                       

  **Age**                                                                                                                   

   19--59                                                 81      70      1.00                --        1.00                --

   60 or more                                             72      45      0.81 (0.56--1.19)   0.277     0.82 (0.55--1.21)   0.323

  **Diagnostic (%)**                                                                                                        

   Rheumatoid arthritis only                              105     91      1.00                --        1.00                --

   Psoriatic arthritis only                               41      22      0.52 (0.23--1.19)   0.123     0.66 (0.28--1.55)   0.342

   RA+PsA                                                 7       2       0.89 (0.55--1.41)   0.609     1.07 (0.64--1.78)   0.790

  **Comorbidity**                                                                                                           

   None                                                   72      58      1.00                --        1.00                --

   1 or more                                              81      57      0.99 (0.69--1.42)   0.946     0.94 (0.64--1.38)   0.735

  **Patient was guided about risk of medication**                                                                           

   No                                                     135     95      1.00                --        1.00                --

   Yes                                                    18      20      0.79 (0.49--1.27)   0.325     0.81 (0.49--1.32)   0.393

  **Health insurance**                                                                                                      

   Private                                                31      25      1.00                --        1.00                --

   Public                                                 122     90      0.95 (0.61--1.48)   0.824     0.91 (0.58--1.43)   0.694

  **Biologic agent**                                                                                                        

   adalimumab                                             63      64      1.00                --        1.00                --

   abatacept                                              7       3       0.60 (0.19--1.90)   0.380     0.52 (0.16--1.68)   0.277

   efalizumab                                             7       2       0.44 (0.11--1.80)   0.254     0.57 (0.13--2.46)   0.454

   etanercept                                             29      23      0.88 (0.55--1.41)   0.592     0.86 (0.53--1.40)   0.531

   infliximab                                             27      15      0.71 (0.40--1.24)   0.230     0.73 (0.40--1.31)   0.286

   rituximab                                              18      7       0.56 (0.26--1.21)   0.140     0.42 (0.18--0.96)   0.044

   tocilizumab                                            2       1       0.66 (0.09--4.77)   0.682     0.56 (0.08--4.05)   0.565

  **Concomitant use of drugs with biologic agents\*\***                                                                     

   No                                                     50      31      1.00                --        1.00                --

   Yes                                                    103     84      1.17 (0.78--1.77)   0.446     1.15 (0.75--1.76)   0.534

  **Concomitant use of DMARDs**                                                                                             

   No                                                     74      50      1.00                --        1.00                --

   Yes                                                    79      65      1.02 (0.61--1.70)   0.935     0.98 (0.58--1.67)   0.944

  **Duration use of biologic agents (months)**                                                                              

   6 to 12 months                                         24      16      1.00                --        1.00                --

   13 months or more                                      129     99      1.08 (0.64--1.83)   0.777     0.95 (0.55--1.62)   0.839
  -----------------------------------------------------------------------------------------------------------------------------------

\**ADR ranked as definite or probable.*

Adjusted to: age, comorbidity and concomitant use of others drugs.

\*\*DMARDs not included.

[**Table 4**](#T4){ref-type="table"} presents the clinical follow-up and outcome in patients with on-going biologic treatments. One hundred fifty-one (95.6%) patients visited a doctor at least once a year, however, 48 patient (30.4%) did not undergo the laboratory tests (complete blood count, liver function test, reactive protein test), while 75 (47.5%) did get radiography done, whereas 58 (36.7%) patients had at least two medical consultations, underwent a laboratory blood test at least once, and had a radiography examination once a year.

###### 

Clinical follow up and outcome judgment in patients with psoriatic arthritis and rheumatoid arthritis still taking biologics.

  ---------------------------------------------------------------------------------------------------------------------
  Outcomes                           abatacept\   adalimumab\   etanercept\   infliximab\   rituximab\   tocilizumab\
                                     (n = 6)\     (n = 75)\     (n = 39)\     (n = 16)\     (n = 19)\    (n = 3)\
                                     n (%)        n (%)         n (%)         n (%)         n (%)        n (%)
  ---------------------------------- ------------ ------------- ------------- ------------- ------------ --------------
  **Annual Review**                                                                                      

  **A) Consults¹**                   6 (100.0)    69 (92.0)     38 (97.4)     16 (100.0)    19 (100.0)   3 (100.0)

  **B) Lab exams²**                  3 (50.0)     54 (72.0)     25 (64.1)     11 (68.7)     14 (73.7)    3 (100.0)

   CBC                               4 (66.7)     71 (94.7)     36 (92.3)     14 (87.5)     16 (84.2)    3 (100.0)

   Liver function test               4 (66.7)     59 (78.7)     30 (76.9)     12 (75.0)     16 (84.2)    3 (100.0)

   CRP test                          3 (50.0)     58 (77.3)     26 (66.7)     11 (68.7)     14 (73.7)    3 (100.0)

  **C) Radiograph³**                 3 (50.0)     43 (57.3)     19 (48.7)     7 (43.7)      10 (52.6)    1 (33.3)

  **Adequate clinical monitoring**                                                                       

  D\) A + B + C                      3 (50.0)     33 (44.0)     9 (23.1)      5 (31.2)      7 (36.8)     1 (33.3)
  ---------------------------------------------------------------------------------------------------------------------

*efalizumab was removed from the market in 2009.*

¹At least two annual medical consults.

²Laboratory blood tests performed at least once a year (CBC -- Complete Blood Count; Liver function tests; CRP test -- C-Reactive Protein test).

³Adiography performed at least once a year.

\*\*Clinical follow up was checked in pts still taking the medication during the interview (n = 158).

Discussion {#s4}
==========

Main Findings {#s4_1}
-------------

The typical long-term users of biological drugs in this study were women aged 19--59 years, with one or more comorbidities, using biological drugs for 13--36 months and having access to public healthcare. Around 40% of the patients using biologics drugs for a long-term, had one or more ADR related to these agents, with 1.6 events per patient. The most common ADRs were administration site reactions, infections and symptoms related to nervous system (headache and neuropathic pain). The occurrence of SAEs was less than 10% of all patients. Nevertheless, the majority of SAEs did not lead to drug discontinuation. Notably, no case of tuberculosis or mortality were detected. None of other risk factors studied were associated with ADRs. Adalimumab was the biological agent most used for the majority of patients and ADRs related with this drug included serious infections disease and injections site reactions. The use of rituximab was related with lower risk of ADR than other agents. Complete clinical follow-up was done by 36.7% of patients, implying that remain the patients, despite receiving government medicines failed to follow-up, according to the official Brazilian guidelines.

Relation to Prior Literature {#s4_2}
----------------------------

Biologicals have become potent and effective therapeutic alternative for many inflammatory and autoimmune diseases like RA and PsA, focus of this cohort population. Their direct and focused effect makes them superior to classic immunosuppressive, whose use is frequently limited by undesirable and often severe generalized adverse effect. Biologic agents targeting specific immune mediators have emerged as other treatment option for patients with RA, PsA and others immune disease who are unresponsive to, or intolerant of, non-biologic systemic agents. ([@B68]; [@B39]).

Furthermore, conventional treatments for PsA have limited efficacy for nail disease, enthesitis or axial involvement, and some are unable to control moderate and severe peripheral joint and skin disease ([@B68]). The introduction of biologic treatments offered the possibility of controlling multiple aspects of these diseases using a single drug, minimizing the need for additional therapies ([@B15]).

Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third line therapies due to a relative lack of long-term safety data. Here, we have reviewed the long-term (\>6 months) safety data. In our study, 35% of patients used biological agents for more than 37 months, reflecting the real scenario of its long-term use in Brazil.

Evidently, the harms of biologics must be balanced against their use benefits, when making a risk--benefit assessment of its use for a patient with systemic autoimmune conditions such as RA or PsA. Patients and physicians worry about risks including not only common ADRs such injection site reactions but also infections that may be less common.

The clinical representation of ADR to biologicals can be ambiguous with regard to pathogenesis of the reaction, because different pathomechanisms may lead to similar symptoms. This is especially important for infusion reactions, whereby no clear clinical distinction between allergic, IgE-mediated, and the more frequent no allergic, most probably complement-mediated reactions are possible. In our study, despite the long-term use of biological agents, mainly the anti-TNFα drugs (infliximab, etanercept and adalimumab) they still have reactions related with administrations. Infusions/Injections site reactions are a major complication of all anti-TNFα drugs with studies showing an incidence rate 3--40% ([@B25]).

The most common cutaneous side effects are injection site reactions, which are often defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection ([@B71]; [@B6]; [@B56]). Administration site reactions can be divided into two types according to their mechanism of action: i. Type α - irritative reactions (immediate) commonly at the injection sites of subcutaneously administered biologics caused by proinflammatory actions of the substances ([@B9]); ii. the Type hypersensitivity reactions categorized into Types I--IV, which are induced by IgE, IgG/IgM, complement or T-cells. Injection site reaction after etanercept injection produce a T-cell-mediated delayed-type hypersensitivity reaction, as approximately 8% of patients developed "recall injection site reaction," reactions at sites were medication was previously injected ([@B56]).

The injections site reactions with etanercept, can occur in up to 37% of patients and characteristically these reactions consist of mild to moderate erythema, pain, pruritus and edema immediately evident or appear within 24--48 h and the mean duration of the reaction is 3--5 d and there is a gradual decrease in frequency and severity with continuation of injections ([@B30]; [@B41]). This didn't happen in the population of this cohort. Patients using adalimumab, etanercept and infliximab more than 6 months in our cohort had 36, 34 and 11% of infusion/injections site reactions. Data from the Hong Kong Biologics Registry that followed up 1,345 patients from 2005--2013 that reported the most frequent SAE (per 100-paties-year) was infusion/injection site reaction (0.75) ([@B40]).

We found that inappropriate injection techniques, injection close to blood vessels, the chemical and physical properties of the injected drug and a reaction to the vehicle component are several causes described in the literature resulting in irritative reactions ([@B9]).

Severe infusion reactions, such as angioedema and shock, have been reported in patients under infliximab therapy. As infliximab is a chimeric human/mouse anti- TNF-α antibody, it may induce the synthesis of neutralizing antibodies which could reduce the efficacy of the drug. Therefore, methotrexate is usually co-administered to control both the rheumatic disease and the development of neutralizing antibodies ([@B42]). In spite of its fully human sequence, the production of antibodies to adalimumab has been also reported, which may reduce the efficacy of the drug and induce the development of adverse drug reactions and exanthema ([@B41]).

However, in the majority of cases the injections site reaction with adalimumab in our study were mild-to-moderate severity, and do not necessitated drug discontinuation.

Studies comparing the intravenous and subcutaneous route of administration of these two agents did not show any difference in clinical efficacy and safety, except that injection site reactions were more common with the subcutaneous access which is the case of adalimumab and etanercept use differently of infliximab that is indicate to infusion use ([@B18]).

Few biologics are associated with a higher rate of some of the ADRs than others, and potential SAEs with short-term and long-term use ([@B61]). The safety of rituximab was consistent with earlier findings, which indicated that there was no increase in ADRs or SAE with its prolonged use (\>5 years) ([@B64]; [@B66]).

This cohort is related to the use of long-term biologicals, which shows that the adverse effects may be different from those studies that indicate short-term adverse effects. The biologic use can increase the risk of serious infections in the first months of treatment with respect to disease-modifying antirheumatic drugs (DMARDs). Data from the British Society for Rheumatology Biologics Register (BSRBR) comparing the risk of serious infections between TNFi-treated patients and traditional DMARD-treated patients showed that the risk of serious infections with TNFi was increased in the first 6 months of initiating therapy for RA and that this risk was higher compared to traditional DMARDs ([@B19]).

Another largest observational studies of infection in patients with autoimmune diseases found that compared to traditional DMARDs, the initiation of TNF-alpha antagonists was not associated with an increased risk of hospitalizations for serious infections ([@B23]).

Serious infections (such as infections requiring hospitalization or intravenous administration of antibiotics, opportunistic infections, including tuberculosis, systemic fungal infections and herpes zoster) were uncommon in population currently using the biological agents for more than six months.

Moreover, long-term use of biological could be related with non-serious infections, mainly of the upper respiratory tract. This ADR were common among the users of biologics in our study, endorsing the findings from earlier studies ([@B55]; [@B66]).

Emerging data also suggest that the incidence of serious infections is dependent on, past history of serious infections, corticosteroids anti-inflammatory doses, and older age as important predictors of risk of serious infections in patients treated with biologics. The duration of treatment is also an important risk factor with the highest rate being observed during the first months of therapy and the risk of infection decreases over time ([@B62]). Our study included patients who used biologics for a prolonged period, which could explain the reduced number of opportunistic infections. No case of tuberculosis was reported.

A study in Latin America showed that the risk of serious infections may vary depending on the region and the characteristics of the patient ([@B49]). This study compared a database not available publicly (BIOBADABRASIL) from Brazil versus a database of Argentina (BIOBADASAR) and showed that the risk of infections in Brazil was decreasing over time, corroborating our findings.

Nowadays, safety profile has changed mainly because we know more about the disease and about biologic agent. Furthermore, not only the function of these composites has to be understood, but also the subjacent immunology (which is very complex). Therefore, current patients do have less prolonged and severe chronic inflammation, key element for decrease of cardiovascular events or malignancy risk.

The delayed reactions related to dysfunction of the cellular response such as autoimmunity or cancer, may appear after many months or years of the cessation of the biologic therapy ([@B37]). However, recent cohort study showed no evidence of change in risk of solid cancer with increasing exposure to biologics in the first five years ([@B38]).

The characteristics of the population of this study are similar to those found in studies carried out in Europe and USA ([@B58]; [@B57]). The most of patients were women, age around 50--55 years old, with at least one comorbidity.

Comorbidities in our study also were similar to those observed in other studies ([@B53]; [@B14]; [@B4]; [@B54]). Patients with RA had more cardiovascular diseases, metabolic diseases like type 2 diabetes mellitus and obesity, and muscle pain rendering in work disabilities. Patients with PsA also had more cardiovascular disease, metabolic disease, inflammatory bowel disease and autoimmune ophthalmic disease. Comorbidities in this study were not related to increase in risk of ADR, as found in patients with only psoriasis in other study ([@B35]).

Considering the high costs of biologic therapies and their adverse events profile in long-term use, the follow up of the patients and individual monitoring is essential ([@B37]). The big problem here with the use of biologics is that the prescription is made by a private doctor and accessibility to the medicine is dependent on public service, disallowing appropriate monitoring.

Furthermore, the wide use of biological agents in modern medicine is a challenge in clinical practices, as it is a case of how fast new therapeutic principles based on novel knowledge and modern techniques can enter clinical practice, and that constant learning is required. Their use often requires a special knowledge and familiarity with the disease to be treated. Scientific data shows that ADRs to these drugs are clinically very heterogeneous. It makes clear, the monitoring of them seems essential ([@B48]; [@B70]). Patients on biologic therapy should be monitored closely with routine blood tests, regular doctor's visit and outcome measures about effectiveness (considering the response to therapy), safety (presence of ADRs and SAEs) and quality of health for prolonged period ([@B16]; [@B50]).

There is a lack of data regarding the best interval for monitoring the patients. We would like to emphasize that we have adopted the recommendations of the Brazilian Clinical Protocols of the time. These are official government protocols, since these medications are only provided in government pharmacies. Most of the patients had medical consultations, and laboratory tests for liver function and blood cell counts, at least annually, according to the recommendations of several guidelines from England, Brazil, Canada, etc. ([@B1]; [@B60]; [@B3]; [@B2]; [@B39], [@B8]; [@B22]). The recommendations for radiography vary according to the adopted guideline. Usually, radiographic assessments are encouraged according to clinical manifestations and discretion of physician ([@B51]). In this study, we decided to follow the Brazilian guideline, and the radiography was assumed as a test for monitoring the progression of tuberculosis.

The most appropriate way to monitor disease activity in PsA is under defined ([@B22]). The recommended core set for PsA comprises of peripheral joints, pain, physical and global function assessment, quality of life and fatigue ([@B32]). It is also recommended that radiographic monitoring for erosions and osteolysis of the hands and feet be done annually ([@B39]).

The effectiveness of the biologics in RA and PsA is unquestionable, but their association with potentially adverse effects can doubt the benefit risk ratio. Therefore, closer monitoring and education of patient and their caregivers about the nature of their condition, benefits and risks of treatment are essential for improving treatment outcome and overall patient satisfaction ([@B16]). The patients need to be advised to report any worsening of symptoms (neurological, cardiac, pulmonary, skin, uveitis and/or malignancies), avoid exposure to potential risk factors for infection, and to promptly communicate to their physician possible signs and symptoms of infection ([@B50]).

Strengths and Limitations {#s4_3}
-------------------------

The strengths of this study included an extensive questionnaire, with questions about previous treatments, diagnosis, comorbidities, and if any adverse effects and its interference with the current treatment. Besides that, our sample size was relatively large, we contacted 305 patients and interviewed 268. Our data was checked twice, as we obtained data about use of medication from the pharmacy records and then confirmed the information from patient interview to ensure its accuracy.

This registry study has mounting importance in medical research and decision-making processes. In fact, despite the inherent limitations of such studies, including the lack of randomization, the relatively high frequency of missing data, and the presence of patients with different diseases, registries usually include larger populations than clinical trials, and therefore have a higher power to detect rare adverse events. In addition, registry studies may better reflect clinical practice with respect to randomized clinical trials, whose results may not immediately be extended to "real-life". Today, several registries in Europe are collecting data on the use of biological Drugs: ARTIS (Antirheumatic Therapies In Sweden), BIOBADASER (Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología, Spain), BSRBR (British Society for Rheumatology Biologics Register, United Kingdon), DANBIO (Danish Database for Biological Therapies in Rheumatology, Denmark), RATIO (Research Axed on Tolerance of Biotherapies, France) etc. Though most patients included in these registries are taking biologic agents for the treatment of RA/PsA, the safety information gained from these sources can be applied in clinical practices ([@B47]).

Brazil have had limited initiatives to build up an important national database linking with important clinical outcomes in RA/PsA/Psoriasis. There are databases restricted to a private insurance sustained by societies of rheumatologist and funding by pharmaceutical industry. An example of this is a multicentre prospective observational cohort in Brazil is the REAL (Rheumatoid arthritis in real life) that is following up 1,300 patients from 11 canters in 4 regions from Brazil, since 2015, funding by Bristol-Myers Squibb, Eli Lily and others pharmaceutical industries ([@B11]). Our study is one of the few studies in Brazil that had access to patients in public health sector, without any conflict of interest with long term follow-up.

Recall bias may have led to obtaining inaccurate information about previous treatments, side effects, and clinical monitoring. We try to reduce this limitation by only asking about the clinical monitoring to those who were still using the biological agents. Another limitation is the fact that ADR were not validated by a treating physician. However, some studies point that data reported by patients are potentially important to support and improve the care ([@B12]; [@B45]). Furthermore, in many countries, pharmacists are recognized as one of the most important healthcare providers in ADR reporting like in the Netherlands, Spain, Portugal, and Korea ([@B63]; [@B31]; [@B69]).

Implications {#s4_4}
------------

This study showed the association of biological agents with ADRs, withdrawals due to adverse events and SAEs in long-term use. Patients using biological agents must be aware of these risks and should be subjected to careful monitoring throughout the treatment to prevent or at least treat a possible ADR. Our data suggests that, patients need comorbidity warning of possible adverse events and recommended enhanced surveillance.

In the long-term, the possible risk of SAE requires caution and further monitoring and investigation. Therefore, review and further investigations of their safety are warranted.
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